Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYTO

Altamira Therapeutics (CYTO) Stock Price, News & Analysis

Altamira Therapeutics logo

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Advanced Chart

Key Stats

Today's Range
$0.30
$0.43
50-Day Range
$0.30
$0.52
52-Week Range
$0.30
$2.47
Volume
753,013 shs
Average Volume
573,097 shs
Market Capitalization
$1.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTO Stock News Headlines

Full Year 2024 Altamira Therapeutics Ltd Earnings Call
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
Altamira Therapeutics Ltd. (CYTOF)
Altamira Therapeutics Ltd (CYTOF)
See More Headlines

CYTO Stock Analysis - Frequently Asked Questions

Shares of Altamira Therapeutics reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Altamira Therapeutics investors own include Plug Power (PLUG), Aridis Pharmaceuticals (ARDS), Soligenix (SNGX), Chemomab Therapeutics (CMMB), CNS Pharmaceuticals (CNSP), Cara Therapeutics (CARA) and Draganfly (DPRO).

Company Calendar

Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTO
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$320,000.00
Price / Cash Flow
N/A
Book Value
$4.56 per share
Price / Book
0.07

Miscellaneous

Free Float
2,958,000
Market Cap
$1.02 million
Optionable
Not Optionable
Beta
1.80
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CYTO) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners